Global CAT Lead Rare Disease

Leading the global expansion of Horizon's Rare Disease portfolio.Interim GM and Representative Director for Japan.Responsible for total operations in KSA and the Greater Gulf Region.

Responsible for the complete product life cycle from Phase I commercial decision through commercialization approval and brand handover in three main therapeutic and business units - Cardiovascular Disease, Alzheimer's Disease, and Pain Management. Manage a cross functional, working group across a diversity of assets and therapeutic disease states. Established a Japan-specific small molecule design and design template blueprint for asset lifecycle planning and pipeline delivery. Additional key responsibilities center on the adoption and implementation of insight-based research, market understanding, forecasting, and customer-centric knowledge and alignment.

Responsible for 13 sales territories throughout Illinois, Iowa, Michigan, and Wisconsin within the Cardiovascular Health Business Unit. Developed business territory objectives, strategies, and business action plans based on access and segmentation for CIGs and HCPs. Designed realignment division in Wisconsin with both the Account-Based Sales team and Cardiovascular Retail team. Selected, coached, and developed 13 sales professionals in a customer-centric, valued-based selling environment.

Oversaw the continued commercialization of olanzapine in the A.C.E. region, as well as working toward the launch of two additional formulations. Managed ZypAdhera product launch Phases 1-4 in the 14 EU and EMS affiliates, and coordinated the approval processes with payer teams for the EU and Emerging Markets for ZypAdhera and Zyprexa Relprevv submissions. Coordinated the olanzapine brand redevelopment and communications strategy via agency, conference, and congress activity in the EU and Emerging Markets.

Consulted on multiple projects across the Neuroscience Brand Portfolio within the EU and the USA. Primary focus areas consisted of webcast and global e-channel developement, the launch of several new class conference and exhibit creations, and the move to a centralized, brand-based global congress strategy. Played a significant team role in the development of sales force marketing materials, patient educational tools, and physician information for schizophrenia and bipolar depression. Played a significant role in the development of the Account-Based Selling Tool and Value-Based Selling propositions for the sales force and Medical Liaison role in EMBU and EU affiliates.

Accountable for the sales results in a territory comprised of 180 Psychiatrists, Neurologists, and Pain Specialists. Account locations centered on state and private hospitals, system- and physician-based clinics, private practice clinics, and CMHC facilities - based in Cincinnati, Ohio and Chicago, Illinois. Ranked 11/140 sales representatives (2006), achieved 110% to Target Earnings for Zyprexa sales (2007), and achieved Top 25% of the nation in sales rankings (2007).

Responsible for the management of 18 public houses and restaurants as well as the coverage of 10 additional Travel Inn franchises. The role specialized in the recruitment, development, and retention of employees from key team members to general management, while managing P&L accounting responsibilities and full operational standards. The annual turnover exceeded £40 million across entire district.